Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673205 | 0.82 | PARP1 (1.00) | PARP1TP53KDM4EALDH1A1DAO | |
| SCHEMBL1133601 | 0.82 | PARP1 (1.00) | PARP1TP53KDM4EALDH1A1DAO | |
| SCHEMBL6429242 | 0.79 | ALDH1A1 (0.49) | PARP1TP53KDM4EALDH1A1MAPT | |
| SCHEMBL30273087 | 0.75 | PARP1 (0.53) | PARP1KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL14974166 | 0.74 | PARP1 (0.57) | PARP1TP53KDM4EALDH1A1NTRK1 | |
| SCHEMBL30902522 | 0.70 | TP53 (1.00) | PARP1TP53NTRK1NTRK3 | |
| SCHEMBL9415441 | 0.70 | PARP1 (0.60) | PARP1TP53ALDH1A1DAONTRK1 | |
| SCHEMBL22046017 | 0.70 | TP53 (0.77) | PARP1TP53ALDH1A1NTRK1NTRK3 | |
| SCHEMBL30809703 | 0.70 | PDE2A (0.67) | PARP1TP53DAOPOLBGRIN2D | |
| SCHEMBL14361434 | 0.70 | PARP1 (0.60) | PARP1TP53ALDH1A1FEN1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000989-A1 | PYRROLO BENZODIAZEPINE DERIVATIVE, AND CONJUGATE, PREPARATION METHOD AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-01-02 | — | — | US | disclosed |
| US-9770520-B2 | Chelate nanoemulsion for MRI | GUERBET (FR) | 2017-09-26 | — | — | US | disclosed |
| EP-2576536-B1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | UNIV QUEENSLAND (AU) | 2016-09-14 | — | — | EP | disclosed |
| US-9199976-B2 | Haematopoietic-prostaglandin D2 synthase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-20150320889-A1 | Vectorised Magnetic Emulsion | GUERBET (FR) | 2015-11-12 | — | — | US | disclosed |
| US-20130309176-A1 | CHELATE NANOEMULSION FOR MRI | UNIVERSITE DE BORDEAUX 1 (FR) | 2013-11-21 | — | — | US | disclosed |
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-30 | — | — | US | disclosed |
| US-6362331-B1 | PYRROLO(2,1-C)(1,4)BENZODIAZEPINE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-03-26 | — | — | US | disclosed |
| EP-0027214-A1 | Imidazodiazepine derivatives, process and intermediates for their preparation, medicaments containing them and their therapeutic application | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | HPGDS, PTGES, PTGIS | PARP1 1089/4885TP53 2786/4885KDM4E 4213/4885 |
| US-20130309176-A1 | CHELATE NANOEMULSION FOR MRI | SGMS1, SGMS2, PHOSPHO1 | PARP1 4322/4885TP53 2065/4885KDM4E 4210/4885 |
| US-20250000989-A1 | PYRROLO BENZODIAZEPINE DERIVATIVE, AND CONJUGATE, PREPARATION METHOD AND USE THEREOF | GABRA5, GABRA4, GABRA2 | PARP1 1948/4885TP53 1269/4885KDM4E 878/4885 |
| US-20150320889-A1 | Vectorised Magnetic Emulsion | SGMS2, TFRC, SGMS1 | PARP1 4540/4885TP53 1824/4885KDM4E 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.